| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Article |
From the Department of Rheumatology,*
Center for
Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; the
Department of Rheumatology,
Astrid Lindgren’s
Children’s Hospital, Karolinska Hospital, Stockholm, Sweden; and the
Laboratory of Biomedical Science,
North Shore
University Hospital, Manhasset, New York
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Collagen-induced arthritis (CIA) in susceptible animal strains constitutes a model of autoimmunity that shares a number of pathological, immunological, and genetic features with RA.7,8 The Dark Agouti (DA) rat is particularly susceptible and offers a stable, reproducible model with an erosive, chronic polyarthritis developing in 100% of immunized animals when induced with homologous collagen type II in the presence of Freund’s incomplete adjuvant.8 This allows studies of immunological events preceding disease onset. Expression of CIA can be enhanced by systemic addition of TNF and IL-1, whereas transforming growth factor {beta} (TGF-{beta}) and antibodies to TNF and IL-1 prevented onset of disease.9-13 Comparative studies of murine CIA suggested that anti-TNF was effective at the onset of arthritis but less so at later stages, whereas anti-IL-1 administration was also highly effective in established disease, including a reduction of cartilage destruction.13,14 Uncoupling of joint swelling and ongoing cartilage damage have been suggested as being separate activities of TNF and IL-1, respectively.14,15
Establishing TNF and IL-1 as therapeutic targets has led to a search for other means of blocking their activities. Recently, a tetravalent guanylhydrazone (CNI-1493) was developed as an inhibitor of macrophage activation, which is mediated by a dose-dependent inhibition of the translation of both TNF and IL-1{beta} mRNAs16-18 via interaction with the p38 MAP kinase.18 In a previous study we could demonstrate that CNI-1493 successfully ameliorated the course of CIA in DA rats after both prophylactic and therapeutic intervention.19
A question that has not been addressed in RA is the kinetic pattern of pro-inflammatory cytokine expression at early stages of disease. To answer this question, detailed longitudinal studies are required, involving multiple sampling of synovial tissue, which for practical reasons preferably is performed in experimental models. Kinetic studies of synovial cytokine production after onset of clinical disease in murine CIA has been reported.20,21 No studies before onset of clinical signs of disease in experimental arthritis have, to our knowledge, previously been published. Neither have studies describing local cytokine expression in rat synovial tissue. The aims of this study were to characterize temporal and spatial changes in synovial cytokine synthesis in DA rats before and after onset of CIA. An additional motive for carrying out this study was to compare the cytokine profile in untreated rats with CIA to that in rats treated prophylactically with the novel cytokine suppressive agent CNI-1493. We have previously developed new immunohistochemical staining methods that enable detection of intracellular cytokine production in rat specimens22 and computerized image analysis for quantification.23,24 Here we have analyzed cryopreserved sections from knee joints for the presence of TNF, IL-1{beta}, and TGF-{beta} at various time points after immunization. Additionally, a phenotypic determination of inflammatory cells in the synovial tissue at the different time points was documented.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Male DA rats, 2 to 3 months old with a mean weight of 220 to 230 g, were kept and bred at the animal unit at the Karolinska Hospital in Stockholm, Sweden. Rats were maintained under climate-controlled conditions with a 12-hour light/dark cycle and were fed standard rodent chow and water ad libitum. The health status of the animal colony was monitored according to the guidelines from the Swedish Veterinary Board and reported free from screened pathogens. All procedures in this project were approved by the Ethical Committee of Stockholm North, Sweden.
Induction and Evaluation of CIA
On day 0, DA rats were immunized intradermally at the base of the tail with rat type II collagen emulsified with Freunds’ incomplete adjuvant (Difco, Detroit, MI), as previously described.25 Using this method, chronic polyarthritis is known to develop in 100% of the animals with mean day of onset of clinical disease day 14 after immunization. Inflammatory lesions affecting both forepaws and hindpaws develop with a progressive deterioration of clinical disease until approximately day 21 after immunization. The severity of arthritis thereafter reaches a plateau, with a subsequent transition to a chronic inflammation with subsiding arthritis indices around day 28 after immunization. This chronic phase includes the development of joint ankylosis as well as flares of active arthritis, which affect both previously affected and new joints.
To follow-up the development of the arthritis, the rats were monitored daily for visual inflammatory signs such as erythema and swelling by two observers using a previously described scoring system.19 Arthritis was graded semiquantitatively with a scale of 0 to 4 for each paw (0, no changes; 1, one type of joint affected; 2, two types of joints affected; 3, three types of joints affected; 4, 3+ maximal erythema and swelling). An arthritis index was calculated for each animal that expresses a cumulative score for all paws with a maximum possible value of 16. A transition from acute to chronic arthritis was established when signs of ankylosis appeared, which was accompanied with a decrease in erythema and swelling and thus in arthritis index.
Although the severity of CIA is generally scored in the paws, profound expression of joint inflammation is concomitantly apparent in the knee joints, which allows a higher degree of standardization of immunohistological sections.
Therapeutic Compound (CNI-1493)
The tetravalent guanylhydrazone CNI-1493 (N,N'-bis (3,5-diacetylphenyl decanediamide tetrakis (amidinohydrazone) tetrahydrochloride, CAS Reg. No.164301-51-3), was synthesized and purified as previously described.16 Animals were injected with CNI-1493 intraperitoneally with doses adjusted according to their daily weight. Control animals received equal volumes with the vehicle alone (sterile, deionized water).
Preparation of Samples for Immunohistochemical Analysis
Forty-five animals were included in this kinetic trial and the kinetics of local cytokine expression was determined in untreated and CNI-1493-treated animals, respectively. Three animals that were not immunized were sacrificed at day 0 as normal controls. Thereafter, 21 immunized animals received 5 mg/kg/day of CNI-1493 adjusted to their daily weight and the remaining 21 immunized animals served as controls receiving vehicle alone. At certain time points after immunization six animals were sacrificed, three untreated and three treated with CNI-1493. Three early time points (3, 6, and 10 days after immunization), the time point of expected onset (day 15 after immunization), the time point for expected maximal severity of arthritis (day 21 after immunization), and the time point for transition to a chronic phase of disease (day 27 after immunization) were selected. The administration of CNI-1493 was withdrawn on day 27 after immunization and three animals from both treatment groups were monitored without treatment until day 38 after immunization, when the trial was terminated.
To examine and compare local immunoreactivity, animals were sacrificed by CO2 asphyxiation, followed by dissection of the patella with adjacent synovium. The synovial specimens were immediately snap-frozen in isopentane prechilled in dry ice and kept at -70°C until sectioned. Saggital cryosections of 7- to 8-µm thickness, encompassing the patella bone with its cartilage and adjacent synovium, were mounted on chromium potassium sulfate and gelatin-coated glass slides (Novakemi, Stockholm, Sweden). Sections were air-dried for 30 minutes and then fixed either for 10 minutes in 2% formaldehyde (Sigma Chemical Co., St Louis, MO) in PBS at room temperature, or in 50% acetone for 30 seconds and 100% acetone for 3 minutes at 4°C. All slides were subsequently stored at -70°C until required for staining. As the arthritic lesions were symmetrical with equal scoring in both hind paws, only one knee specimen per rat was studied.
Immunohistochemical Detection of Intracellular Cytokine Production in Formaldehyde-Fixed Sections
The formaldehyde-fixed cryopreserved sections were stained for
intracellular expression of cytokines as previously
described.19,24
Briefly, permeabilization of the cell
membranes was performed by the use of Earle’s balanced salt solution
(Gibco Ltd., Paisley, UK) supplemented with saponin 0.1% (Riedel de
Haen AG, Seelze, Germany) in all subsequent washes and incubation
steps. Endogenous peroxidase activity was blocked for 1 hour in the
dark with 1% hydrogen peroxide and 2% sodium nitride dissolved in
Earle’s balanced salt solution-saponin. Sections were thereafter
blocked with either 2% normal goat sera or 2% normal human AB-sera
for 30 minutes to reduce background staining because of nonspecific
binding sites. Subsequently, endogenous biotin was blocked with avidin
for 30 minutes and biotin for an additional 15 minutes (avidin/biotin
blocking kit; Vector Laboratories, Burlingame, CA), both substituted
with 0.1% saponin. Thereafter sections were incubated overnight in a
humidified chamber with 50 µl of rat cytokine-specific antibodies: a
polyclonal ligand-affinity purified goat anti-rat IL-1{beta} (AF-501-NA;
R&D Systems, Minneapolis, MN), a polyclonal antigen
affinity-purified rabbit anti-rat TNF-
(catalog no. CT 061; U-CyTech
BV, Utrecht University, The Netherlands) and a monoclonal mouse
(IgG1) anti-rat TGF-{beta} (originally obtained from
American Tissue Cultures Collection (ATCC) as a hybridoma and cultured
and purified in our laboratory), used at a final concentration of 2 to
5 µg/ml. Slides were then incubated for 30 minutes with appropriate
biotin-labeled antibody (Jackson ImmunoResearch, West Grove, PA):
donkey anti-goat (catalog no. 705-066-147), donkey anti-rabbit (catalog
no. 711-066-152), or donkey anti-mouse (catalog no. 715-066-151). They
were all Fab2-fragmented and used at a final
concentration of 1:1,000. Thereafter 50 µl of a solution of
Vectastain avidin-biotin-horseradish peroxidase (Vectastain Elite,
ABC-kit; Vector Laboratories), prepared according to the directions of
the manufacturer, was applied for 30 minutes. After final washes in
Earle’s balanced salt solution-saponin, the substrate diaminobenzidine
(peroxidase substrate kit, Vector) was added. A color reaction was
stopped after 5 minutes by washes in deionized water. Sections were
counterstained with Mayer’s hematoxylin and mounted with buffered
glycerol.
Specificity of Cytokine Staining
In each assay, controls for specificity of cytokine stainings were included, based on parallel staining studies omitting the primary antibody or using primary isotype prematched immunoglobulin of irrelevant antigen specificity at the same concentration as the cytokine-detecting antibodies. Additionally, blocking experiments were performed by preabsorption of the cytokine-specific antibodies with their respective target cytokines at a 1:10 molar ratio overnight at 4°C before application to tissues.
Immunohistochemical Detection of Cell Surface Markers on Acetone-Fixed Sections
Phenotypic characterization of cells present in the synovial
tissue was performed on separate acetone-fixed slides as previously
described.19
The primary antibodies used for cell surface
staining were monoclonal mouse antibodies directed to MHC II (OX-6),
/{beta}-T cell receptor (R73), OX-33 (an isoform of CD45 specific for
rat B-cells), and ED1 (a surface membrane antigen expressed on rat
macrophages, monocytes and dendritic cells). OX-6 and R73 were
originally obtained from ATCC as hybridomas, and cultured and purified
in our laboratory. OX-33 and ED1 were purchased from Serotec Ltd
(Oxford, UK).
Microscopic Evaluation and Quantification with Computer-Aided Image Analysis
Cytokine and phenotype expression was quantified with a computerized image analysis system, as previously described,23,24 by calculating the total positively stained area for a given cytokine or surface marker. Stained tissue sections were evaluated with a Polyvar II microscope (Reichert-Jung, Vienna, Austria) equipped with a three-chip charged couple device color camera (DXC-750P; Sony Corporation, Tokyo, Japan) that digitized the microscope images to be processed in a Quantimet 550S image analyzer (Leica Cambridge, Cambridge, UK) linked to a PC computer. In the present study, analysis of an entire section was defined as all synovial tissue within five microscopic fields (1.2 mm) above and below the patella bone at a magnification of x250, which typically involved a total of 10 to 42 microscopy fields, depending on the width of synovial tissue. The stainings for the different cytokines and surface markers were examined in sequential sections to ensure that comparable tissue areas were studied. Using same color detecting thresholds, control quantifications gave reproducible values of the positively stained areas with an intra-assay variation of 2 to 5%. All animals were studied in at least two to three separate staining experiments for each given cytokine or surface marker. Quantifications between stainings for a given antigen on separate sections gave an interassay variation of 5 to 15%.
Statistical Analyses
The differences between CNI-1493-treated and control animals were compared using the Mann Whitney U test. P values were based on comparisons between the groups at a given time point. A value of P < 0.05 was considered as significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The animals had no signs of clinical arthritis at the early time
points studied (days 3, 6, and 10 after immunization). At the time
point of expected disease onset (day 15 after immunization) there were
12 remaining animals in both groups. Seven of the untreated animals had
clinical signs of arthritis, whereas all CNI-1493-treated animals
remained healthy. One of the untreated animals remained healthy
throughout the trial so that the incidence never reached 100%. At day
21 after immunization eight of nine untreated and one of nine of
CNI-1493-treated animals had developed arthritis. Five of six animals
had arthritis in both groups day 27 after immunization, with an
arthritis index of 8 in the untreated and 4.8 in the CNI-1493-treated
animals. Because three untreated animals had developed ankylosis,
indicating a transition from acute to a chronic inflammation, treatment
was stopped day 27 after immunization. However, as we in an earlier
study19
had experienced that the severity of arthritis
promptly increased after CNI-1493 treatment withdrawal, we monitored
three rats from each group for an additional 10 days without any
therapy to study clinical and immunological consequences (Figure 1)
.
|
In sections from animals sacrificed before onset of disease
(before day 15 after immunization), the synovial tissue appeared
nonproliferative, containing only a few cell layers. Some scattered
cells stained positive for MHC II and occasionally for the macrophage
marker ED1 (Figure 2, D and E)
. These
cells were located mainly as isolated events in the deeper synovial
area. An additional MHC II expression of cells in the lining layer was
noted from day 6 after immunization on scattered cells and, at later
time points, on larger proportions of cells. No cells stained positive
for /{beta}-TCR (Figure 2F)
or OX-33 at these earlier time points.
|
. A large fraction of corresponding areas was
ED1+ (Figure 2E
, also see Figure 4
). The
predominance of MHC II+ and
ED1+ cells was evident at all stages of disease,
after the clinical course reaching a maximal value at day 21 in the
untreated control animals. The ED1+ cells were
observed within the sublining layer and in the pannus area. Only a few
cells were ED1+ in the thickened synovial-lining
layer, but a large fraction was MHC II+. A
similar distribution of MHC II+ and
ED1+ cells was recorded in sections of
CNI-1493-treated animals, but as the degree of inflammation and thus of
cell infiltration dominated in untreated animals, a larger number of
cells stained positive with significant differences at indicated time
points (Figure 2, D and E)
.
|
.
Scattered cells expressing /{beta}-TCR were observed from disease onset
(day 15 after immunization), mostly in the deeper layers of the synovia
at some distance from cartilage and bone. A stable number of
/{beta}-TCR+ cells were noted thereafter
throughout the monitoring period. Occasional
OX-33+ B cells could be detected at later time
points in both two groups (data not included). Location and Morphology of Cytokine Expression before Onset of Arthritis
TNF and IL-1{beta} expressing cells could be recognized already 3
days after immunization in all six studied animals, which preceded the
expected onset of clinical disease by >10 days. These cells were
mainly located in the synovial-lining layer, but also to a lesser
extent within blood vessel endothelium and occasionally as isolated
sublining cells (Figure 3)
. At this early
time point no MHC II or ED1 expression could be detected within the
lining layer. A similar distribution of TNF and IL-1{beta}-producing cells
was noted day 6 and day 10 after immunization. In some animals, an
additional IL-1{beta} production was noted in cells with fibroblast-like
morphology within deeper areas of synovial tissue. At these time
points before disease onset the synovia was a thin membrane containing
only a few cell layers, explaining the low values for total positively
stained area. This early disease-preceding synthesis of TNF and IL-1{beta}
in the lining layer was not influenced by CNI-1493 intervention (Figure 2, A and B)
.
|
A more evident production of TNF and IL-1{beta} coincided with onset
and progression of clinical disease in untreated animals (Figure 2, A and B
; Figure 4, A and B
). Accordingly,
the maximal production was seen day 21 after immunization,
corresponding to the peak of paw swelling and to manifestation of
erosive changes in cartilage and bone. TNF production dominated
quantitatively with values up to fourfold that of IL-1{beta}. Particularly
in sections with cartilage damage and pannus formation, the local
cytokine expressed was mostly TNF although IL-1{beta} was also detected. A
decline in production of these pro-inflammatory cytokines occurred day
27 after immunization, when clinically a transition of the acute
inflammation to a chronic phase occurred. The distribution of TNF- and
IL-1{beta}-positive cells was similar with cells detected both within the
synovial-lining layer and the deeper synovial tissue. Additionally,
scattered cells were distributed in the interstitial tissue,
perivascularly, and within vessel endothelium for both cytokines.
Prophylactic therapy with CNI-1493 resulted in a reduction of both
pro-inflammatory cytokines, but especially of TNF. At day 21 after
immunization the reduction of TNF was 10-fold in CNI-1493-treated
animals as compared to untreated animals. Disease onset was delayed in
the treatment group. TNF synthesis was down-regulated even at later
time points when CNI-1493-treated animals displayed signs of clinical
arthritis (Figure 2A
and Figure 4E
). Intervention with CNI-1493 also
resulted in reduction of IL-1{beta} production (Figure 2B)
but the effect
was not as evident as for that on TNF.
In addition to cytoplasmatically stained cells, we observed
immunoreactivity extending over extracellular areas surrounding
cytokine-producing cells. This was particularly evident when staining
for TNF, as the detected positive area for TNF at certain time points
exceeded the positive area occupied by the presumed producer cells
(ED1+) in sequentially stained sections (Figure 4, A and C)
. The specificities of the extracellular and the
intracellular cytokine immunoreactivities were verified by their
complete inhibition in blocking experiments with pre-absorption of the
cytokine-specific antibody with recombinant target cytokine before
staining. No TNF- or IL-1{beta}-producing cells could be detected in
animals that were not immunized.
Distribution and Kinetics of TGF-{beta}-Producing Cells Locally in the Joints
A low TGF-{beta} expression was detected in synovial sections of
untreated animals from disease onset and onward. The weak staining
observed was localized to the sublining layer on day 15 after
immunization and at later time points an additional expression in the
lining layer could also be detected. However, in CNI-1493-treated
animals a distinct up-regulation of TGF-{beta} was documented that was
statistically significant on days 10, 27, and 38 after immunization. At
the later time points an intense immunoreaction for TGF-{beta} was
recorded within the synovial lining and sublining layer (Figure 2C
and
Figure 5A
).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Earlier studies in murine models have suggested a sequential cytokine
expression coinciding with clinical disease, with TNF expression
preceding IL-1{beta}.21
However, in our rat model TNF and
IL-1{beta} appeared simultaneously, followed by a synchronous peak and
decline in expression (Figure 2, A and B)
. To our knowledge this is the
first demonstration of early local cytokine production preceding
inflammatory cell infiltration and clinical arthritis. The producer
cells of this initial disease-preceding cytokine expression were
synoviocytes within the synovial-lining layer, but also cells within
blood vessel endothelium (Figure 3)
. This underlines the potential role
of TNF in up-regulating the expression of adhesion molecules on
vascular endothelial cells. TNF has also been demonstrated to be
chemotactic for monocytes and neutrophils, causing accumulation of
these inflammatory cells in the synovium.26
After disease
onset macrophages predominated as the major cytokine-producing cells, a
finding consistent with earlier studies in murine arthritis
models21
and RA synovial tissue.24,27
Although the clinical severity of CIA is generally scored in the paws, profound expression of joint inflammation is concomitantly apparent in the knee joints. A great advantage of analysis of knee joints is the higher degree of standardization of immunohistological sections and the possibility for detailed analysis of cytokine expression in multiple sequential sections. Paw specimens need to be decalcified before cutting, which prevents the usage of our methodology, because the delicate intracellular morphology will be deranged by the chemicals needed for decalcification. In addition, there are major difficulties obtaining a serial of sequential sections with comparable morphology.
After onset of clinical disease, the number of TNF-producing cells
clearly exceeded that of IL-1{beta}, especially in the acute phase of
inflammation but also in the chronic phase (Figure 2, A and B)
. This
quantitative TNF dominance compared to IL-1{beta} in CIA is the opposite
result to that we have recorded in human RA using the same
methodology.24
One should be cautious with the overall
interpretation of data obtained with different antibodies, in view of
potential differences in immunostaining capacity. However, we have
recently reported that kinetic patterns and quantitative responses of
TNF and IL-1{beta} production were very similar in cultured rat spleen
cells22
using the technology of this study to previous
results in human blood cell cultures28
and in mouse spleen
cultures,29
indicating satisfactory sensitivity of both
antibodies. It could also be argued that studies of synovial CIA
specimens at much later time points might show a more congruent picture
to that in RA with lower TNF expression. The cytokine interplay may be
different in acute and advanced arthritis. But in the present trial, we
have focused on the time span that is commonly used in evaluating new
therapeutic approaches. This further implicates a need for caution when
extrapolating findings in animal models to human RA.
Therapeutic cytokine-blocking studies in murine CIA revealed that TNF neutralization gave major suppressive effects when treatment was started shortly before disease onset, but only a marginal effect when given after the arthritis was fully expressed, whereas anti-IL-1 was also highly effective in established disease.13,14 These results could be explained in quantitative terms considering that in experimental arthritis the quantitatively dominating TNF production makes IL-1 a more accessible target for therapeutic down-regulation. The treatment strategy in human RA might be the opposite because the quantitatively higher IL-1 production might require relatively higher doses of IL-1Ra than in CIA for beneficial effects.
We have previously shown that the novel macrophage pacifying compound
CNI-1493 can prevent and diminish the severity of CIA.19
Intervention with CNI-1493 did not have any effect on the early,
quantitatively low, disease-preceding synthesis of TNF and IL-1{beta} in
the lining layer. After disease onset, coinciding with macrophage
infiltration in the synovium, CNI-1493 clinically resulted in a delayed
disease onset and a decrease in arthritis severity with a clear
reduction of swelling and a synovitis that was less extensive at all
time points when compared to untreated animals. We demonstrate a
profound down-regulation of TNF in CNI-1493-treated animals as well as
a reduced IL-1{beta} synthesis although not as evident as for TNF. These
findings are in accordance with earlier in vitro studies of
CNI-1493, when suppression of several other pro-inflammatory cytokines,
including IL-1 and IL-1{beta}, required 10 to 20 times higher
concentrations than needed for TNF inhibition.17
The
profound inhibitory effect of CNI-1493 on TNF synthesis in this
TNF-dominating disease implicates that the down-regulatory potential of
CNI-1493 in rheumatoid synovitis might even be underestimated based on
our present clinical results.
An unexpected finding in this study was that prophylactic intervention
with CNI-1493 resulted in an up-regulation of TGF-{beta} (Figure 2C
and
Figure 5
). TGF-{beta} has been mainly implicated as an anti-inflammatory
mediator in the synovium with a modulatory role during the progression
of arthritis.30
Release of TGF-{beta} by synoviocytes could
be an important regulatory mechanism for ameliorating the destruction
induced by IL-1 and TNF of cartilage and bone. The balance of
proinflammatory cytokines and anti-inflammatory cytokines will dictate
the magnitude of the inflammatory response. We hypothesize that
CNI-1493-mediated up-regulation of TGF-{beta} production might be one of
the mechanisms by which CNI-1493 ameliorates CIA. However, the question
remains unanswered whether this TGF-{beta} up-regulation was a direct
effect of CNI-1493 on producer cells, or was indirectly caused by the
reduced levels of TNF and IL-1{beta}. The effect of p38 MAP kinase on
cytokine expression has been studied most extensively in activated
monocytes/macrophages. Stimulators of the phosphorylation of p38 MAP
kinase (eg, lipopolysaccharide) cause the release of TNF and IL-1, but
do not always activate the release of TGF-{beta}, which is constitutively
produced by monocyte cultures. p38 MAP kinase has been implicated in
the regulation of the release of TGF-,31
but evidence
for the direct regulation of TGF-{beta} by p38 is lacking. In contrast to
previous reports of CIA in rats,32
only a low number of
cells stained positive for TGF-{beta} in synovial sections of untreated
animals in our study. A possible explanation for this could be that the
antibody used in this study recognized TGF-{beta}1 and TGF-{beta}3 but not
TGF-{beta}2. This TGF-{beta} up-regulation apparent in the CNI-1493-treated
animals contradicts the notion that the down-regulatory effects on TNF
and IL-1{beta} were caused by nonspecific toxicity of the compound.
In conclusion, this study provides new insights into early cytokine expression by the unequivocal demonstration of local TNF and IL-1{beta} synthesis in resident cells more than a week before disease onset and inflammatory cell infiltration. We also determined that after disease onset, TNF production clearly exceeded that of IL-1{beta}, a result in contrast to that in human RA in which the reverse situation is established. Characterizing animal models and elucidating differences are crucial prerequisites when extrapolating findings in experimental systems to the human clinical situation.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by grants from the Swedish Medical Research Council, the Swedish National Cancer Foundation, the Swedish Association against Rheumatism, B. Dahlin’s Foundation, B. von Kantzow’s Foundation, the Freemason Lodge Barnhuset in Stockholm, N. Svartz’ Foundation, af Ugglas’ Foundation, and King Gustaf V’s Foundation.
Accepted for publication October 17, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
—a pivotal role in rheumatoid arthritis? Br J Rheum 1992, 31:293-298 (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110[Medline]
and transforming growth factor {beta} during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992, 89:7375-7379, anti-IL-1/{beta}, and IL-1Ra. Arthritis Rheum 1996, 39:797-809[Medline]
in experimental arthritis: separate activity of interleukin 1{beta} in chronicity and cartilage destruction. Ann Rheum Dis 1999, 58:140-148
) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats. Clin Exp Immunol 1999, 115:32-41[Medline]
and TNF- in activated splenocytes by intracellular immunostaining. Biotech Histochem 2000, 75:101-109[Medline]
in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991, 34:1125-1132[Medline]
This article has been cited by other articles:
 |
|
 |
|
  M. Yamaguchi, N. Aihara, T. Kojima, and K. Kasai RANKL Increase in Compressed Periodontal Ligament Cells from Root Resorption. J. Dent. Res., August 1, 2006; 85(8): 751 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brenner, H.-C. Meng, N. C. Yarlett, B. Joe, M. M. Griffiths, E. F. Remmers, R. L. Wilder, and P. S. Gulko The Non-MHC Quantitative Trait Locus Cia5 Contains Three Major Arthritis Genes That Differentially Regulate Disease Severity, Pannus Formation, and Joint Damage in Collagen- and Pristane-Induced Arthritis J. Immunol., June 15, 2005; 174(12): 7894 - 7903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bolon, G. Campagnuolo, L. Zhu, D. Duryea, D. Zack, and U. Feige Interleukin-1{beta} and Tumor Necrosis Factor-{alpha} Produce Distinct, Time-dependent Patterns of Acute Arthritis in the Rat Knee Vet. Pathol., May 1, 2004; 41(3): 235 - 243. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
